Sirtuin 6 inhibition protects against glucocorticoid-induced skeletal muscle atrophy by regulating IGF/PI3K/AKT signaling
Related Experiment Video
Updated: Aug 28, 2025

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells
Published on: June 12, 2017
Sneha Mishra1, Claudia Cosentino2, Ankit Kumar Tamta1
1Department of Microbiology and Cell Biology, Indian Institute of Science, Bengaluru, India.
Abstract:
Chronic activation of stress hormones such as glucocorticoids leads to skeletal muscle wasting in mammals. However, the molecular events that mediate glucocorticoid-induced muscle wasting are not well understood. Here, we show that SIRT6, a chromatin-associated deacetylase indirectly regulates glucocorticoid-induced muscle wasting by modulating IGF/PI3K/AKT signaling. Our results show that SIRT6 levels are increased during glucocorticoid-induced reduction of myotube size and during skeletal muscle atrophy in mice. Notably, overexpression of SIRT6 spontaneously decreases the size of primary myotubes in a cell-autonomous manner. On the other hand, SIRT6 depletion increases the diameter of myotubes and protects them against glucocorticoid-induced reduction in myotube size, which is associated with enhanced protein synthesis and repression of atrogenes. In line with this, we find that muscle-specific SIRT6 deficient mice are resistant to glucocorticoid-induced muscle wasting. Mechanistically, we find that SIRT6 deficiency hyperactivates IGF/PI3K/AKT signaling through c-Jun transcription factor-mediated increase in IGF2 expression. The increased activation, in turn, leads to nuclear exclusion and transcriptional repression of the FoxO transcription factor, a key activator of muscle atrophy. Further, we find that pharmacological inhibition of SIRT6 protects against glucocorticoid-induced muscle wasting in mice by regulating IGF/PI3K/AKT signaling implicating the role of SIRT6 in glucocorticoid-induced muscle atrophy.
Insights
SIRT6 protein levels increase during muscle wasting caused by glucocorticoids. Reducing SIRT6 protects muscles by enhancing protein synthesis and blocking atrophy, revealing SIRT6 as a key regulator of glucocorticoid-induced muscle atrophy.
Area of Science:
- Biochemistry
- Molecular Biology
- Physiology
Background:
- Chronic stress hormone activation, like glucocorticoids, causes skeletal muscle wasting.
- The precise molecular mechanisms behind glucocorticoid-induced muscle atrophy remain unclear.
Purpose of the Study:
- To investigate the role of SIRT6, a chromatin-associated deacetylase, in glucocorticoid-induced skeletal muscle wasting.
- To elucidate the molecular pathways modulated by SIRT6 in muscle atrophy.
Main Methods:
- Assessed SIRT6 expression during glucocorticoid treatment and in mouse models of muscle atrophy.
- Utilized cell-autonomous overexpression and depletion of SIRT6 in primary myotubes.
- Generated muscle-specific SIRT6 deficient mice.
- Investigated the impact of pharmacological SIRT6 inhibition.
Main Results:
- SIRT6 levels rise with glucocorticoid-induced myotube atrophy and in mouse skeletal muscle atrophy.
- SIRT6 depletion enhances myotube diameter, protein synthesis, and represses atrogenes, conferring protection against glucocorticoid-induced wasting.
- Muscle-specific SIRT6 deficient mice exhibit resistance to glucocorticoid-induced muscle wasting.
- SIRT6 deficiency activates IGF/PI3K/AKT signaling via increased IGF2 expression, leading to FoxO transcription factor repression.
Conclusions:
- SIRT6 plays a critical role in mediating glucocorticoid-induced skeletal muscle wasting.
- Modulating SIRT6 activity, particularly through pharmacological inhibition, offers a potential therapeutic strategy against muscle atrophy.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
TGF - β Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The JAK-STAT Signaling Pathway

